您的位置: 首页 > 2018年5月 第49卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

同轴微切口白内障超声乳化联合雷珠单抗玻璃体腔注射治疗白内障并糖尿病性黄斑水肿的临床观察

The combination of micro incision phacoemulsification and intravitreal ranibizumab in patients with cataract and diabetic macular edema

来源期刊: 广州医药 | 29-32 发布时间:2021-12-01 收稿时间:2025/11/13 17:21:47 阅读量:37
作者:
关键词:
白内障同轴微切口糖尿病性黄斑水肿雷珠单抗
CataractMicro incisionDiabetic macular edemaRanibizumab
DOI:
10.3969/j.issn.1000-8535.2018.03.008
收稿时间:
2018-01-03 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 观察同轴微切口超声乳化白内障术联合玻璃体腔注射雷珠单抗治疗糖尿病性黄斑水肿的临床疗效。方法 选择2014年7月—2016年11月在我院就诊的68例(72只眼)患有老年性白内障合并糖尿病性黄斑水肿患者,分为2组,治疗组(32例,34只眼)行同轴微切口超声乳化白内障术联合玻璃体腔注射雷珠单抗;对照组(36例,38只眼)单纯行白内障超声乳化摘除;观察指标包括术前、术后最佳矫正视力、眼压及黄斑中心凹视网膜厚度,观察时间为术前、术后1周、1月、3月、6月、12月。结果 术后两组最佳矫正视力与术前相比差异有统计学意义(P<0.01);术前及术后1周2组最佳矫正视力无差异,术后1月、3月、6月、12月治疗组最佳矫正视力均优于对照组;术前2组患者黄斑中心凹视网膜厚度相比无明显差异,术后各个时间点治疗组黄斑中心凹视网膜厚度均低于对照组,二者相比差异有差异性(P均<0.001);两组患者术前及术后眼压无差异(P<0.05)。结论 对老年性白内障合并糖尿病性黄斑水肿患者,术中联合玻璃体腔注射雷珠单抗,可减轻术后黄斑水肿,改善患者术后中、远期视力。
Objective To assess the safety and efficiency of combination of micro incision phacoemulsification (PHACO) surgery and intravitreal ranibizumab injection in patients with cataract and diabetic macular edema. Methods The selected 68 patients (72 eyes) with age-related cataract and diabetic macular edema were randomly divided into two groups: the PHACO and intravitreal Ranibizumab injection (treatment group, 32 cases, 34 eyes), and only PHACO (control group, 36 cases, 38 eyes) in our hospital from July 2014 to November 2016. Preoperative and postoperative best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were recorded. The time points included preoperative day, 1 week, 1 month, 3 months, 6 months and 12months after surgery. Results Postoperative BCVA during the follow-up period was higher than the initial BCVA in both groups (P<0.01). There was no statistically significant difference between both groups in BCVA at pre-operation and 1 week after surgery. In the treatment group, the postoperative BCVA was significantly higher than the control group at 1 month, 3 months, 6 months and 12months after operation. The mean CMT in the treatment group was lower than the control group in all the follow-up time. There was no statistically significant difference in IOP between two groups preoperatively and postoperatively during the follow-up period (P>0.05). Conclusion Additional intravitreal ranibizumab injection after PHACO surgery reduced macular edema and preserved this improvement in the mid-and-long term of BCVA.
1、 MENCHINI U, BANDELLO F, de ANGELIS V, et al. Ranibizumab for visual impairment due to diabetic macular edema: real-world evidence in the italian population (pride study) [J]. J Ophthalmol, 2015(2015): 324841. MENCHINI U, BANDELLO F, de ANGELIS V, et al. Ranibizumab for visual impairment due to diabetic macular edema: real-world evidence in the italian population (pride study) [J]. J Ophthalmol, 2015(2015): 324841.
2、 MITCHELL P, MASSIN P, BRESSLER S, et al. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study[J]. Curr Med Res Opin,2015,31(11): 1967-1975. MITCHELL P, MASSIN P, BRESSLER S, et al. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study[J]. Curr Med Res Opin,2015,31(11): 1967-1975.
3、 FERRONE P J, JONISCH J. Comparison of ranibizumab 0.5 mg versus 1.0 mg for the treatment of patients with clinically significant diabetic macular edema: a randomized, clinical trial[J]. Ophthalmic Surg Lasers Imaging Retina,2016,47(6): 536-543. FERRONE P J, JONISCH J. Comparison of ranibizumab 0.5 mg versus 1.0 mg for the treatment of patients with clinically significant diabetic macular edema: a randomized, clinical trial[J]. Ophthalmic Surg Lasers Imaging Retina,2016,47(6): 536-543.
4、 MOSHFEGHI D M, KAISER P K, MICHELS S, et al. The role of anti-vegf therapy in the treatment of diabetic macular edema[J]. Ophthalmic Surg Lasers Imaging Retina,2016,47(6 Suppl): S4-S14. MOSHFEGHI D M, KAISER P K, MICHELS S, et al. The role of anti-vegf therapy in the treatment of diabetic macular edema[J]. Ophthalmic Surg Lasers Imaging Retina,2016,47(6 Suppl): S4-S14.
5、 DHOOT D S, AVERY R L. Vascular endothelial growth factor inhibitors for diabetic retinopathy[J]. Curr Diab Rep,2016,16(12): 122. DHOOT D S, AVERY R L. Vascular endothelial growth factor inhibitors for diabetic retinopathy[J]. Curr Diab Rep,2016,16(12): 122.
6、 李琳娜, 张晓峰. 糖尿病黄斑水肿的发病机制及治疗研究进展[J]. 临床眼科杂志,2014,22(1): 86-90. 李琳娜, 张晓峰. 糖尿病黄斑水肿的发病机制及治疗研究进展[J]. 临床眼科杂志,2014,22(1): 86-90.
7、 MEHTA H, GILLIES M C, FRASER-BELL S. Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review[J]. Clin Exp Ophthalmo,2016,44(4): 335-339. MEHTA H, GILLIES M C, FRASER-BELL S. Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review[J]. Clin Exp Ophthalmo,2016,44(4): 335-339.
8、 李辰, 宋兵. 白内障超声乳化手术联合术后激光光凝治疗老年白内障伴糖尿病黄斑水肿的临床观察[J]. 中国老年学杂志,2017,37(9): 2264-2266. 李辰, 宋兵. 白内障超声乳化手术联合术后激光光凝治疗老年白内障伴糖尿病黄斑水肿的临床观察[J]. 中国老年学杂志,2017,37(9): 2264-2266.
9、 杨波, 宋艳. 超声乳化联合曲安奈德玻璃体腔内注射治疗白内障合并糖尿病黄斑水肿[J]. 国际眼科杂志,2015,15 (9): 1532-1535. 杨波, 宋艳. 超声乳化联合曲安奈德玻璃体腔内注射治疗白内障合并糖尿病黄斑水肿[J]. 国际眼科杂志,2015,15 (9): 1532-1535.
10、 盛丽娜. 白内障超声乳化术后糖尿病性黄斑水肿的变化[J]. 眼科新进展,2008 (9): 703. 盛丽娜. 白内障超声乳化术后糖尿病性黄斑水肿的变化[J]. 眼科新进展,2008 (9): 703.
11、 STEWART M W. Treatment of diabetic retinopathy: Recent advances and unresolved challenges[J]. World J Diabetes, 2016, 7(16): 333-341. STEWART M W. Treatment of diabetic retinopathy: Recent advances and unresolved challenges[J]. World J Diabetes, 2016, 7(16): 333-341.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录